Derek C Chang1, Jan Klimas, Evan Wood, Nadia Fairbairn. 1. British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada (DCC, JK, EW, NF); Department of Family Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada (DCC); School of Medicine, University College Dublin, Belfied, Dublin, Ireland (JK); and Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada (EW, NF).
Abstract
BACKGROUND: Relapse to opioid use is common after rapid opioid withdrawal. As a result, short-term tapers of opioid agonist/partial agonist medications, such as methadone and buprenorphine/naloxone, are no longer recommended by recent clinical care guidelines for the management of opioid use disorder. Nonetheless, rapid tapers are still commonplace in medically supervised withdrawal settings. CASE SUMMARY: We report a case of an individual with opioid use disorder who was prescribed a rapid buprenorphine/naloxone taper in a medically supervised withdrawal facility and who had a subsequent opioid overdose and death after discharge. DISCUSSION: The fatal outcome in this case study underscores the potential severe harms associated with use of rapid tapers. Given the increased overdose risk, tapers should be avoided and continuing care strategies, such as maintenance pharmacotherapy, should be initiated in medically supervised withdrawal settings.
BACKGROUND: Relapse to opioid use is common after rapid opioid withdrawal. As a result, short-term tapers of opioid agonist/partial agonist medications, such as methadone and buprenorphine/naloxone, are no longer recommended by recent clinical care guidelines for the management of opioid use disorder. Nonetheless, rapid tapers are still commonplace in medically supervised withdrawal settings. CASE SUMMARY: We report a case of an individual with opioid use disorder who was prescribed a rapid buprenorphine/naloxone taper in a medically supervised withdrawal facility and who had a subsequent opioid overdose and death after discharge. DISCUSSION: The fatal outcome in this case study underscores the potential severe harms associated with use of rapid tapers. Given the increased overdose risk, tapers should be avoided and continuing care strategies, such as maintenance pharmacotherapy, should be initiated in medically supervised withdrawal settings.
Authors: Thomas Kerr; Nadia Fairbairn; Mark Tyndall; David Marsh; Kathy Li; Julio Montaner; Evan Wood Journal: Drug Alcohol Depend Date: 2006-09-07 Impact factor: 4.492
Authors: James D Wines; Richard Saitz; Nicholas J Horton; Christine Lloyd-Travaglini; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2007-02-05 Impact factor: 4.492
Authors: Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2018-06-19 Impact factor: 4.492
Authors: Lawrence H Yang; Margaux M Grivel; Bradley Anderson; Genie L Bailey; Mark Opler; Liang Yi Wong; Michael D Stein Journal: J Subst Abuse Treat Date: 2019-01-09